WO2020187340A3 - Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva - Google Patents

Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva Download PDF

Info

Publication number
WO2020187340A3
WO2020187340A3 PCT/CU2020/050002 CU2020050002W WO2020187340A3 WO 2020187340 A3 WO2020187340 A3 WO 2020187340A3 CU 2020050002 W CU2020050002 W CU 2020050002W WO 2020187340 A3 WO2020187340 A3 WO 2020187340A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
lymphocytes
expansion
differentiation
adoptive transfer
Prior art date
Application number
PCT/CU2020/050002
Other languages
English (en)
French (fr)
Other versions
WO2020187340A2 (es
Inventor
Kalet LEÓN MONZÓN
Galia Magela MONTALVO BEREAU
George Coukos
Melita IRVING
Elisabetta CRIBIOLI
Yaquelín ORTIZ MIRANDA
Ángel de Jesús CORRIA OSORIO
Original Assignee
Centro De Inmunologia Molecular
Ludwig Institute For Cancer Research Ltd
Centre Hospitalier Universitaire Vaudois
University Of Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020217033073A priority Critical patent/KR20220012224A/ko
Priority to JP2021555590A priority patent/JP2022524882A/ja
Priority to CA3133736A priority patent/CA3133736A1/en
Priority to CN202080020973.5A priority patent/CN113785048A/zh
Application filed by Centro De Inmunologia Molecular, Ludwig Institute For Cancer Research Ltd, Centre Hospitalier Universitaire Vaudois, University Of Lausanne filed Critical Centro De Inmunologia Molecular
Priority to MX2021011120A priority patent/MX2021011120A/es
Priority to EP20757209.0A priority patent/EP3940063A2/en
Priority to AU2020242520A priority patent/AU2020242520B2/en
Priority to EA202192447A priority patent/EA202192447A1/ru
Priority to BR112021018100A priority patent/BR112021018100A2/pt
Priority to US17/439,293 priority patent/US20220152107A1/en
Priority to SG11202109574Q priority patent/SG11202109574QA/en
Publication of WO2020187340A2 publication Critical patent/WO2020187340A2/es
Publication of WO2020187340A3 publication Critical patent/WO2020187340A3/es
Priority to CONC2021/0013127A priority patent/CO2021013127A2/es
Priority to ZA2021/07758A priority patent/ZA202107758B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2317—Interleukin-17 (IL-17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

En la presente invención se describe un método para obtener linfocitos T y células NK con el fenotipo deseado en la transferencia adoptiva de células para la terapia del cáncer. Especialmente, se basa en estrategias para inducir una señalización preferencial a través del receptor de IL2 de afinidad intermedia, con lo cual se logra expandir las células con el fenotipo de memoria central deseado. El método de la presente invención es útil en la obtención de linfocitos infiltrantes de tumor, TCR o de receptores quiméricos ingenierizados de células T empleados en el tratamiento del cáncer.
PCT/CU2020/050002 2019-03-15 2020-03-09 Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva WO2020187340A2 (es)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP20757209.0A EP3940063A2 (en) 2019-03-15 2020-03-09 Method for the expansion and differentiation of t lymphocytes and nk cells in adoptive transfer therapies
CA3133736A CA3133736A1 (en) 2019-03-15 2020-03-09 Method for the expansion and differentiation of t lymphocytes and nk cells in adoptive transfer therapies
CN202080020973.5A CN113785048A (zh) 2019-03-15 2020-03-09 用于扩增和分化在过继转移疗法中的t淋巴细胞和nk细胞的方法
EA202192447A EA202192447A1 (ru) 2019-03-15 2020-03-09 Способ размножения и дифференцировки т-лимфоцитов и nk-клеток в методах лечения с адоптивным переносом
MX2021011120A MX2021011120A (es) 2019-03-15 2020-03-09 Metodo para la expansion y diferenciacion de linfocitos t y celulas nk en terapias de transferencia adoptiva.
JP2021555590A JP2022524882A (ja) 2019-03-15 2020-03-09 養子移入療法（Ａｄｏｐｔｉｖｅ ｔｒａｎｓｆｅｒ ｔｈｅｒａｐｉｅｓ）におけるＴリンパ球及びＮＫ細胞の拡大増殖及び分化のための方法
AU2020242520A AU2020242520B2 (en) 2019-03-15 2020-03-09 Method for the expansion and differentiation of T lymphocytes and NK cells in adoptive transfer therapies
KR1020217033073A KR20220012224A (ko) 2019-03-15 2020-03-09 입양 전달 요법에서 t 림프구 및 nk 세포의 확장 및 분화를 위한 방법
BR112021018100A BR112021018100A2 (pt) 2019-03-15 2020-03-09 Métodos para a diferenciação e expansão de linfócitos t e células nk, para enriquecimento e expansão ex vivo de linfócitos e para tratar um câncer, uso do método, células, e, composição de células
US17/439,293 US20220152107A1 (en) 2019-03-15 2020-03-09 Method for expansion and differentiation of t lymphocytes and nk cells for adoptive transfer therapies
SG11202109574Q SG11202109574QA (en) 2019-03-15 2020-03-09 Method for the expansion and differentiation of t lymphocytes and nk cells in adoptive transfer therapies
CONC2021/0013127A CO2021013127A2 (es) 2019-03-15 2021-09-30 Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
ZA2021/07758A ZA202107758B (en) 2019-03-15 2021-10-13 Method for the expansion and differentiation of t lymphocytes and nk cells in adoptive transfer therapies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2019000021A CU20190021A7 (es) 2019-03-15 2019-03-15 Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
CU2019-0021 2019-03-15

Publications (2)

Publication Number Publication Date
WO2020187340A2 WO2020187340A2 (es) 2020-09-24
WO2020187340A3 true WO2020187340A3 (es) 2021-04-15

Family

ID=72087852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2020/050002 WO2020187340A2 (es) 2019-03-15 2020-03-09 Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva

Country Status (17)

Country Link
US (1) US20220152107A1 (es)
EP (1) EP3940063A2 (es)
JP (1) JP2022524882A (es)
KR (1) KR20220012224A (es)
CN (1) CN113785048A (es)
AR (1) AR118369A1 (es)
AU (1) AU2020242520B2 (es)
BR (1) BR112021018100A2 (es)
CA (1) CA3133736A1 (es)
CO (1) CO2021013127A2 (es)
CU (1) CU20190021A7 (es)
EA (1) EA202192447A1 (es)
MX (1) MX2021011120A (es)
SG (1) SG11202109574QA (es)
TW (1) TW202102667A (es)
WO (1) WO2020187340A2 (es)
ZA (1) ZA202107758B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ766453A (en) 2018-02-01 2022-02-25 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2023004004A1 (en) * 2021-07-23 2023-01-26 Merck Sharp & Dohme Llc Il-2 muteins for treating cancer or infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053109A1 (en) * 2007-10-24 2009-04-30 Anne Letsch Antigen-specific t-cell preparations from bone marrow
EP2639241A2 (en) * 2010-11-12 2013-09-18 Centro de Inmunologia Molecular Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
WO2017136818A2 (en) * 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1956080E (pt) * 2005-08-08 2011-12-30 San Raffaele Centro Fond Uso de il-7 e il-15 para a modificação genética de linfócitos t da memória

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053109A1 (en) * 2007-10-24 2009-04-30 Anne Letsch Antigen-specific t-cell preparations from bone marrow
EP2639241A2 (en) * 2010-11-12 2013-09-18 Centro de Inmunologia Molecular Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
WO2017136818A2 (en) * 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANUGRAHA RAJAGOPALAN ET AL: "Aptamer-Targeted Attenuation of IL-2 Signaling in CD8 + T Cells Enhances Antitumor Immunity", MOLECULAR THERAPY, vol. 25, no. 1, 1 January 2017 (2017-01-01), pages 54 - 61, XP055530337, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2016.10.021 *
ARON M. LEVIN ET AL: "Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'", NATURE, vol. 484, no. 7395, 25 March 2012 (2012-03-25), pages 529 - 533, XP055214333, ISSN: 0028-0836, DOI: 10.1038/nature10975 *
BLAESCHKE FRANZISKA ET AL: "Induction of a central memory and stem cell memory phenotype in functionally active CD4+and CD8+CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+acute lymphoblastic leukemia", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 67, no. 7, 31 March 2018 (2018-03-31), pages 1053 - 1066, XP036529046, ISSN: 0340-7004, [retrieved on 20180331], DOI: 10.1007/S00262-018-2155-7 *
CARMENATE T ET AL: "Human IL-2 mutein with higher antitumor efficacy than wild type IL-2", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 190, no. 12, 15 June 2013 (2013-06-15), pages 6230 - 6238, XP002745304, ISSN: 0022-1767, [retrieved on 20130515], DOI: 10.4049/JIMMUNOL.1201895 *
HALLETT WILLIAM H D ET AL: "Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell-Mediated Antitumor Responses", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 14, no. 10, 1 October 2008 (2008-10-01), pages 1088 - 1099, XP085251410, ISSN: 1083-8791, DOI: 10.1016/J.BBMT.2008.08.001 *

Also Published As

Publication number Publication date
AU2020242520A1 (en) 2021-11-11
TW202102667A (zh) 2021-01-16
CO2021013127A2 (es) 2022-03-18
ZA202107758B (en) 2022-12-21
EA202192447A1 (ru) 2021-12-07
WO2020187340A2 (es) 2020-09-24
AU2020242520B2 (en) 2024-04-04
CA3133736A1 (en) 2020-09-24
US20220152107A1 (en) 2022-05-19
CN113785048A (zh) 2021-12-10
KR20220012224A (ko) 2022-02-03
EP3940063A2 (en) 2022-01-19
BR112021018100A2 (pt) 2022-02-08
CU20190021A7 (es) 2020-10-20
MX2021011120A (es) 2022-01-18
JP2022524882A (ja) 2022-05-10
SG11202109574QA (en) 2021-10-28
AR118369A1 (es) 2021-09-29

Similar Documents

Publication Publication Date Title
WO2020187340A3 (es) Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
Zeh III et al. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer
HK1215269A1 (zh) 基因修飾的人自然殺傷細胞系
US10172717B2 (en) Artificial disc
WO2017201432A3 (en) Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
WO2019034933A3 (en) Head stabilization system and method with cassette features
WO2012127464A3 (en) Constitutively activated t cells for use in adoptive cell therapy
WO2007017172A3 (en) Orthopaedic medical device
ATE407646T1 (de) Interspinales implantat
MX2021001009A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana.
Watzl et al. Natural killer cell regulation-beyond the receptors
PL3944373T3 (pl) Bateria wtórna, sposób jej wytwarzania i urządzenie zawierające baterię wtórną
MX2022002521A (es) Metodos y composiciones para la modificacion y administracion de linfocitos.
MX2020003129A (es) Composiciones celulares que comprenden linfocitos t específicos para antígenos para una terapia adoptiva.
MY196500A (en) Transfer Jig And Surface Treatment Apparatus Using Same
PT3774286T (pt) Aparelho para impressão 3d de tipo fotopolimerização de baixo para cima com sistema de membrana elástica independente e referência de inclinação e métodos relativos de uso
Kim et al. Adoptive cell therapy of melanoma with cytokine-induced killer cells
Kovacsovics-Bankowski et al. Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis
PH12021551142A1 (en) Suicide gene
HUE065042T2 (hu) Szekunder elem és a szekunder elemet tartalmazó készülék
MX2021008525A (es) Polipeptidos de interleucina-34 (il-34) mutados y sus usos en terapia.
EP3872903A4 (en) COMPOSITE GRAPHITE MATERIAL, SECONDARY BATTERY, DEVICE AND PREPARATION PROCESS
FR3032347B1 (fr) Prothese totale de genou avec couple de frottement ceramique sur ceramique et plateau mobile en ceramique.
AU2020242254A1 (en) Lnterleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells
Shams et al. IL-35 and IL-10 dependent immunoregulatory lymphocytes in Rheumatoid Arthritis

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2021555590

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3133736

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021018100

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020757209

Country of ref document: EP

Effective date: 20211015

ENP Entry into the national phase

Ref document number: 2020242520

Country of ref document: AU

Date of ref document: 20200309

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021018100

Country of ref document: BR

Free format text: COM BASE NA PORTARIA 405 DE 21/12/2020, SOLICITA-SE QUE SEJA APRESENTADO, EM ATE 60 (SESSENTA)DIAS, NOVO CONTEUDO DE LISTAGEM DE SEQUENCIA POIS O CONTEUDO APRESENTADO NA PETICAO NO870210101824 DE 04/11/2021 POSSUI INFORMACOES DIVERGENTES AO PEDIDO EM QUESTAO NO CAMPO110

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20757209

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112021018100

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210913